Dr. Michelle Howard – Case Study In Early Cancer Detection & Prevention

Dr. Michelle Howard, Case Study

Suspected of having Breast Cancer in 2012, as a result of prior year’s 3D Mammograms and Ultrasound studies which contained suspicious images, compelled her to look more deeply into her state of health.

In 2013 a stereotactic surgical tissue biopsy was performed on Dr. Howard, which revealed inconclusive pathology, but was nevertheless highly suspicious of cancer, specifically Ductal Carcinoma In Situ.

Dr. Howard was offered interventions ranging from Bi-lateral Mastectomy, as well as a wait and see approach.

Upon discovery of liquid biopsy as a possible method of determining more specifically a tissue of origin, their use was employed.

The selection of the OncoBlot liquid biopsy test, which measures the concentration of ENOX2 in blood to better determine the presence of cancer, returned a negative result for Breast Cancer, but a positive result for Ovarian Cancer & Malignant Melanoma.

Two other liquid biopsy tests, which included Nagalase, and Circulating Tumor Cells also helped confirm the presence of cancer, using different markers.

Hence, Dr. Howard elected to receive ovarian resection, though subsequent surgical pathology report was negative for gross tumor cells.

Multiple skin biopsies were performed to find evidence of Melanoma. All biopsies were negative.

Dr. Howard learned about prescription Aldara Cream (https://www.mayoclinic.org/drugs-supplements/imiquimod-topical-route/side-effects/drg-20067474?p=1) which is both diagnostic and therapeutic.

She applied Aldara Cream to one arm, then the other arm, until the Melanoma was found, just below the neck line on her upper chest.

After ovarian cancer/melanoma were treated surgically and topically, liquid biopsies continued to demonstrate the presence of sub-clinical cancer, for those two tissues of origin.

Dr. Howard discovered that her Circulating Tumor Cells, remained present at very low concentrations, post treatment.

Dr. James Morre, who invented the OncoBlot test, discovered mesothelioma lung cancer could be detected in blood, on the average, 6.6 years prior to clinical presentation of disease (https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4724078/).

Further research needs to be conducted to determine the lead time from when cancer is initially detected in blood, to when it can be detected via pathology and imaging.

The goal now is to manage Dr. Howard’s disease at Stage Zero, and ensure that it never presents clinically.

Dr. Howard’s Progression of Test Results

August 16, 2016

Nagalase: 1.14
Oncoblot: Positive for ovarian & melanoma

November 18, 2016

Nagalase: 1.01
Oncoblot: Positive for ovarian cancer only

February 14, 2017

Nagalase: 0.99
Oncoblot: Positive for ovarian cancer only

Introduced February 14, 2017

Capsol-T (EGCG + Capsaicin)

May 28, 2017

Nagalase: 0.80
Oncoblot: Negative for all Cancers

December 22, 2017

Nagalase: 0.73
Oncoblot: Negative for all Cancers

July 27, 2021

RGCC CTC: 2.6 cells/7ml of blood

Phil Garner – Case Study In Using Liquid Biopsy to Manage Prostate Cancer

Phil Garner, Case Study

As a result of seeing a urologist regularly in 2017, there developed a suspicion of a recurrence of a prior prostate cancer, based on clinical analysis. Notably, Phil had a robot prostatectomy two years prior, and had been informed he was cured of prostate cancer.  Nevertheless, his PSA was increasing, but there were no signs of cancer by radiological scans. Phil’s doctor recommended radiation prophylactically, to prevent a full-blown recurrence of his prostate cancer.

Phil Garner is a 68 year old ex-athlete who outwardly appears much younger and healthier than most men his age. Phil spent almost thirty years in Major League Baseball, first as a player and then as a manager.

Given Phil’s reticence to jump right back into standard of care (radiation), he elected to use a metabolic intervention in the form of inducing a state of nutritional ketosis, along with a protocol of supplementation which would help mediate both glucose and glutamate metabolism.

Along side these changes in nutrition and supplementation, Nagalase and Oncoblot blood tests would be leveraged consistently, pursuant to generating insight into the state of disease, at a sub-clinical level.

Ketones and Glucose levels would be monitored on a daily basis, via the use of Abbott’s Precision Xtra glucose/ketone hand held monitor,

Worth considering as well, there were several ancillary medical issues that needed to be addressed. Phil has Rheumatoid Arthritis and was given a testosterone implant by a wellness doctor. Phil had recently started the steroid Prednisone and Hydroxychloroquine for the Rheumatoid Arthritis.  He was weaned from both Prednisone and Hydroxychloroquine, but it was too difficult to remove the testosterone implant.

Phil’s Running Nagalase and Oncoblot Tests
Feb 28, 2017
Nagalase: 1.39
Oncoblot: Positive

June 5, 2017
Nagalase: 1.34
Oncoblot: Positive

August 24, 2017
Nagalase: 1.29
Oncoblot: Positive

*Capsol-T (EGCG & Capsaicin) Introduced after August 24, 2017

November 6, 2017
Nagalase:  0.97
Oncoblot: Negative

January 26, 2018
Nagalase: 0.87

April 5, 2018
Nagalase: 1.10

July 2, 2018
Nagalase: 1.22

*Note normal Nagalase level is less than 0.95

The introduction of Capsol-T in combination with sustained nutritional ketosis appears to have made a significant difference in the downward trend of Nagalase levels. Phil’s Ultra-Sensitive PSA returned to 0.08 normal, after about 6 weeks of lifestyle changes and supplements.

However, as is often the case with interventions which require ongoing attendance to rigorous nutritional protocols, around November 2017, Phil became less strict with his diet and lifestyle choices.

Sometime after January 26, 2018 Phil stopped taking Capsol-T, and started taking Prednisone and Hydroxychloroquine because of pain caused by his Rheumatoid Arthritis. We repeated his Nagalase level in early April 2018, and his Nagalase was starting to trend higher.

Notably, as per ongoing normal labs, and Phil’s insulin level was down to 5, but his cholesterol went over 300 from his ketogenic diet, though triglycerides  normal.

Phil’s Rheumatoid Factor and hs-CRP decreased into the normal range throughout this process.

Today, Phil continues to explore novel methods of managing his disease- he is now pursuing a regimen of combining Doxycycline, Lipitor, Metformin and Mebendazol, and still demonstrates no signs of clinical disease.